The potential efficacy of atezolizumab plus bevacizumab treatment for hepatocellular carcinoma patients with macroscopic portal vein tumor thrombus.

IF 1.7 4区医学 Q2 SURGERY

Surgery Today Pub Date : 2025-07-01 Epub Date: 2025-02-11 DOI:10.1007/s00595-025-03009-x

Shohei Komatsu, Yoshihiko Yano, Kazuki Terashima, Yoshimi Fujishima, Jun Ishida, Nobuaki Ishihara, Takanori Matsuura, Tomoaki Okimoto, Yuzo Kodama, Takumi Fukumoto

{"title":"The potential efficacy of atezolizumab plus bevacizumab treatment for hepatocellular carcinoma patients with macroscopic portal vein tumor thrombus.","authors":"Shohei Komatsu, Yoshihiko Yano, Kazuki Terashima, Yoshimi Fujishima, Jun Ishida, Nobuaki Ishihara, Takanori Matsuura, Tomoaki Okimoto, Yuzo Kodama, Takumi Fukumoto","doi":"10.1007/s00595-025-03009-x","DOIUrl":null,"url":null,"abstract":"Purpose: The prognosis of patients with hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) in the first-order or main trunk/contralateral branches (Vp3/4) is poor. The present study aimed to clarify the real-world data of atezolizumab plus bevacizumab treatment (Ate/bev) for HCC patients with Vp3/4 PVTT.Methods: The subjects of this study were 22 consecutive HCC patients with Vp3/4 PVTT, who were treated with Ate/bev. Survival rates and radiological responses were evaluated based on the modified albumin-bilirubin (mALBI) grade [mALBI 1 + 2a (1/2a) versus 2b + 3 (2b/3)] using the modified Response Evaluation Criteria in Solid Tumors.Results: The median survival time of the 22 patients was 15.0 months, with 1- and 2-year survival rates of 62.7% and 49.3%, respectively. The objective response (OR) rates of patients with mALBI 1/2a and 2b/3 were 91.7% (11/12) and 10.0% (1/10), respectively, with a significant difference (p < 0.001). The 2-year survival rates of patients with mALBI 1/2a and 2b/3 were 78.6% and 20.0%, respectively, with a significant difference (p = 0.0041).Conclusion: Ate/bev was effective for treating HCC patients with Vp3/4 PVTT. OR rate and MST were favorable, particularly for patients with preserved liver function (mALBI 1/2a), suggesting its great potential for the treatment of HCC in patients with Vp3/4 PVTT.","PeriodicalId":22163,"journal":{"name":"Surgery Today","volume":" ","pages":"900-908"},"PeriodicalIF":1.7000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Surgery Today","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00595-025-03009-x","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/11 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: The prognosis of patients with hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) in the first-order or main trunk/contralateral branches (Vp3/4) is poor. The present study aimed to clarify the real-world data of atezolizumab plus bevacizumab treatment (Ate/bev) for HCC patients with Vp3/4 PVTT.

Methods: The subjects of this study were 22 consecutive HCC patients with Vp3/4 PVTT, who were treated with Ate/bev. Survival rates and radiological responses were evaluated based on the modified albumin-bilirubin (mALBI) grade [mALBI 1 + 2a (1/2a) versus 2b + 3 (2b/3)] using the modified Response Evaluation Criteria in Solid Tumors.

Results: The median survival time of the 22 patients was 15.0 months, with 1- and 2-year survival rates of 62.7% and 49.3%, respectively. The objective response (OR) rates of patients with mALBI 1/2a and 2b/3 were 91.7% (11/12) and 10.0% (1/10), respectively, with a significant difference (p < 0.001). The 2-year survival rates of patients with mALBI 1/2a and 2b/3 were 78.6% and 20.0%, respectively, with a significant difference (p = 0.0041).

Conclusion: Ate/bev was effective for treating HCC patients with Vp3/4 PVTT. OR rate and MST were favorable, particularly for patients with preserved liver function (mALBI 1/2a), suggesting its great potential for the treatment of HCC in patients with Vp3/4 PVTT.

查看原文本刊更多论文

阿特唑单抗联合贝伐单抗治疗肝细胞癌伴宏观门静脉肿瘤血栓的潜在疗效

目的：肝细胞癌（HCC）合并门静脉肿瘤血栓（PVTT）在一级或主干/对侧分支（Vp3/4）的预后较差。本研究旨在阐明atezolizumab加贝伐单抗治疗（Ate/bev）治疗Vp3/4 PVTT HCC患者的真实数据。方法：本研究的对象是22例连续接受Ate/bev治疗的Vp3/4 PVTT HCC患者。生存率和放射学反应是基于修改后的白蛋白胆红素（mALBI）分级[mALBI 1 + 2a (1/2a) vs 2b + 3 (2b/3)]，使用修改后的实体瘤反应评价标准进行评估。结果：22例患者的中位生存时间为15.0个月，1年和2年生存率分别为62.7%和49.3%。mALBI 1/2a和2b/3患者的客观缓解率（OR）分别为91.7%（11/12）和10.0%(1/10)，差异有统计学意义(p)。结论：Ate/bev对Vp3/4 PVTT治疗HCC患者有效。OR率和MST均较好，特别是对于肝功能保存的患者（mALBI 1/2a），提示其在Vp3/4 PVTT患者的HCC治疗中具有很大的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Surgery Today 医学-外科

CiteScore

4.90

自引率

4.00%

发文量

208

审稿时长

1 months

期刊介绍： Surgery Today is the official journal of the Japan Surgical Society. The main purpose of the journal is to provide a place for the publication of high-quality papers documenting recent advances and new developments in all fields of surgery, both clinical and experimental. The journal welcomes original papers, review articles, and short communications, as well as short technical reports("How to do it"). The "How to do it" section will includes short articles on methods or techniques recommended for practical surgery. Papers submitted to the journal are reviewed by an international editorial board. Field of interest: All fields of surgery.